... 2018 ; 42 : 102 – 10 . 188. Tang J , Wennerberg K , Aittokallio T . What is synergy? The Saariselka agreement revisited . Front Pharmacol 2015 ; 6 : 181 . 189. Chou TC . Theoretical basis, experimental design, and computerized simulation of synergism...

... expression library of human ORFs . Nat Methods 2011 ; 8 : 659 – 61 . 25. Chou TC . Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies . Pharmacol Rev 2006 ; 58 : 621 – 81 . 26. Wisitpitthaya S...

...   TC .  Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies . Pharmacol Rev   2006 ; 58 : 621 – 81 . 48. Menezes   WP , Silva   VAO , Gomes   INF , Rosa   MN , Spina   MLC , Carloni   AC , et al   Loss...

... Nicotinamide N-Methyltransferase and miR-449a in EGFR-TKI-resistant non-small-cell lung cancer cells . Mol Ther Nucleic Acids   2018 ; 11 : 455 – 67 . 36. Chou   TC .  Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies...

..., experimental design, and computerized simulation of synergism and antagonism in drug combination studies . Pharmacol Rev   2006 ; 58 : 621 – 81 . 26. Ianevski   A , Giri   AK , Aittokallio   T .  SynergyFinder 2.0: visual analytics of multi-drug combination synergies . Nucleic Acids Res...

... has a dual function in the p53/Mdm2 circuit . Oncogene   2015 ; 34 : 5729 – 38 . 16. Chou   TC .  Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies . Pharmacol Rev   2006 ; 58 : 621 – 81 . 17. Stacey   SN...

... loss of heterozygosity is common in the cell lines but uncommon in primary tumors . BMC Genomics   2011 ; 12 : 443 . 31. Chou   TC .  Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies . Pharmacol Rev   2006 ; 58 : 621...

... . 21. Chou   TC .  Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies . Pharmacol Rev   2006 ; 58 : 621 – 81 . 22. Chou   TC .  Drug combination studies and their synergy quantification using the Chou-Talalay...

... Keyserlingk   NG , Elbling   L , et al   Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24) . Biochem Pharmacol   2006 ; 71 : 426 – 40 . 18. Chou   T-C .  Theoretical basis, experimental design, and computerized simulation...

... sensitivity . Nature   2012 ; 483 : 603 – 7 . 39. Chou   TC .  Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies . Pharmacol Rev   2006 ; 58 : 621 – 81 . 40. Chou   TC .  Drug combination studies and their synergy...

... . 10. Chou   T-C .  Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies . Pharmacol Rev   2006 ; 58 : 621 – 81 . 11. Cavalli   F , Hansen   HH , Kaye   SB , European Society for Medical Oncology . Textbook...

... Biol   1976 ; 59 : 253 – 76 . 42. Chou   TC .  Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies . Pharmacol Rev   2006 ; 58 : 621 – 81 . 43. Weisenberger   DJ , Campan   M , Long   TI , Kim   M...

..., and computerized simulation of synergism and antagonism in drug combination studies . Pharmacol Rev   2006 ; 58 : 621 – 81 . 6. Das   TK , Dana   D , Paroly   SS , Perumal   SK , Singh   S , Jhun   H , et al   Centrosomal kinase Nek2 cooperates with oncogenic pathways to promote...

... or sigmoidicity) and D_m (potency or ED₅₀) values from each drug and their combinations allow computerized simulation of synergism or antagonism at all doses and effect levels at different time points for therapeutic efficacy and for toxicity. The isobolograms at different effect levels...

... Biol   2008 ; 35 : 1 – 2 . 30. Chou   TC .  Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies . Pharmacol Rev   2006 ; 58 : 621 – 81 . 31. Yokoyama   Y , Dhanabal   M , Griffioen   AW , Sukhatme   VP...

... , Abrego   J , Haridas   D , Mishra   A , Souchek   J , et al   MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism . Oncotarget   2015 ; 6 : 19118 – 31 . 25. Chou   TC .  Theoretical basis, experimental design, and computerized simulation of synergism...

... , Mintoff   C , Virassamy   B , et al   Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer . Nat Commun   2017 ; 8 : 606 . 20. Chou   TC .  Theoretical basis, experimental design, and computerized simulation of synergism...

.... Effectiveness of different concentration of each single therapy and its combination with LGK974 was determined to create a drug-response-curve due to the computerized simulation of synergism and antagonism in drug combination studies (Chou, 2006). A reporter assay for canonical WNT/β-catenin signaling was used...

...-dependent kinase-1 (PDK1) inhibitors . J Med Chem   2011 ; 54 : 1871 – 95 . 26. Chou   TC .  Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies . Pharmacol Rev   2006 ; 58 : 621 – 81 . 27. Chou   TC , Talalay   P...

..., experimental design, and computerized simulation of synergism and antagonism in drug combination studies . Pharmacol Rev   2006 ; 58 : 621 – 81 . 30. Chou   TC , Talalay   P .  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors . Adv...